Russell Investments Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-5,600
| Closed | -$210K | – | 3385 |
|
|
2021
Q1 | $210K | Buy |
5,600
+1,332
| +31% | +$33.2K | ﹤0.01% | 2812 |
|
|
2020
Q4 | $72K | Sell |
4,268
-1,721
| -29% | -$21.6K | ﹤0.01% | 2897 |
|
|
2020
Q3 | $28K | Hold |
5,989
| – | – | ﹤0.01% | 3124 |
|
|
2020
Q2 | $36K | Buy |
+5,989
| New | +$24.7K | ﹤0.01% | 3014 |
|
|
2020
Q1 | – | Sell |
-84,321
| Closed | -$385K | – | 3202 |
|
|
2019
Q4 | $385K | Buy |
84,321
+83,821
| +16,764% | +$332K | ﹤0.01% | 2499 |
|
|
2019
Q3 | $2K | Buy |
+500
| New | +$2.74K | ﹤0.01% | 3011 |
|
|
2019
Q2 | – | Sell |
-8,500
| Closed | -$114K | – | 3007 |
|
|
2019
Q1 | $114K | Buy |
8,500
+7,100
| +507% | +$81K | ﹤0.01% | 2715 |
|
|
2018
Q4 | $13K | Sell |
1,400
-4,800
| -77% | -$57.1K | ﹤0.01% | 2886 |
|
|
2018
Q3 | $86K | Sell |
6,200
-300
| -5% | -$4.46K | ﹤0.01% | 2774 |
|
|
2018
Q2 | $103K | Sell |
6,500
-600
| -8% | -$10.5K | ﹤0.01% | 2736 |
|
|
2018
Q1 | $122K | Sell |
7,100
-11,769
| -62% | -$230K | ﹤0.01% | 2731 |
|
|
2017
Q4 | $425K | Sell |
18,869
-1,101
| -6% | -$35.4K | ﹤0.01% | 2488 |
|
|
2017
Q3 | $817K | Sell |
19,970
-25,496
| -56% | -$800K | ﹤0.01% | 2236 |
|
|
2017
Q2 | $1.37M | Sell |
45,466
-47,343
| -51% | -$1.48M | ﹤0.01% | 1957 |
|
|
2017
Q1 | $3.35M | Sell |
92,809
-93,923
| -50% | -$4.14M | 0.01% | 1457 |
|
|
2016
Q4 | $9.44M | Buy |
+186,732
| New | +$9.81M | 0.02% | 880 |
|
Russell Investments Group's FPRX Position: Q2 2021 in Review
Russell Investments Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 5,600 shares — an estimated $210K sold.
Russell Investments Group first reported a position in FPRX in Q4 2016 and held it in 16 quarters. The position peaked at $9.44M in Q4 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Russell Investments Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Russell Investments Group sold 5,600 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $210K.
- Russell Investments Group first reported a position in Five Prime Therapeutics, Inc. in Q4 2016 and held it in 16 quarters.
- Russell Investments Group's Five Prime Therapeutics, Inc. position peaked at $9.44M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Russell Investments Group's 13F filing for Q2 2021, filed 4 Aug 2021.